ANNALS OF SURGICAL ONCOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2236516, encodeId=69a922365167a, content=接收后ASO author reflection必须要写吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e15555908, createdName=ms4000000190354659, createdTime=Tue Nov 12 15:24:17 CST 2024, time=2024-11-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2241419, encodeId=7de122414192e, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审，是不是显示三个编辑就送审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ec8472153, createdName=ms2000000534427564, createdTime=Sun Dec 08 21:36:20 CST 2024, time=2024-12-08, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2237265, encodeId=4e71223e265a0, content=该期刊接受包括论著、摘要、信件和临床试验等多种形式的文章。 审稿周期相对较短，一般为2.8个月左右。 大家在投稿前，一定要仔细阅读ASO的投稿指南，了解期刊的格式要求、引用风格、图表规范等方面的内容。 ASO支持开放获取（OA）模式出版，但需要版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 18:45:07 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：胸部肿瘤临床文章 4.17投稿 5.5意见返回来（小修） 5.17投回去 6.2接收，还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=)]

2024-11-12 ms4000000190354659 来自山东省

接收后ASO author reflection必须要写吗

17 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2236516, encodeId=69a922365167a, content=接收后ASO author reflection必须要写吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e15555908, createdName=ms4000000190354659, createdTime=Tue Nov 12 15:24:17 CST 2024, time=2024-11-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2241419, encodeId=7de122414192e, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审，是不是显示三个编辑就送审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ec8472153, createdName=ms2000000534427564, createdTime=Sun Dec 08 21:36:20 CST 2024, time=2024-12-08, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2237265, encodeId=4e71223e265a0, content=该期刊接受包括论著、摘要、信件和临床试验等多种形式的文章。 审稿周期相对较短，一般为2.8个月左右。 大家在投稿前，一定要仔细阅读ASO的投稿指南，了解期刊的格式要求、引用风格、图表规范等方面的内容。 ASO支持开放获取（OA）模式出版，但需要版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 18:45:07 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：胸部肿瘤临床文章 4.17投稿 5.5意见返回来（小修） 5.17投回去 6.2接收，还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=)]

2024-12-28 ms5000000711521518 来自新疆

请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审

2 0

[GetPortalCommentsPageByObjectIdResponse(id=2236516, encodeId=69a922365167a, content=接收后ASO author reflection必须要写吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e15555908, createdName=ms4000000190354659, createdTime=Tue Nov 12 15:24:17 CST 2024, time=2024-11-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2241419, encodeId=7de122414192e, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审，是不是显示三个编辑就送审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ec8472153, createdName=ms2000000534427564, createdTime=Sun Dec 08 21:36:20 CST 2024, time=2024-12-08, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2237265, encodeId=4e71223e265a0, content=该期刊接受包括论著、摘要、信件和临床试验等多种形式的文章。 审稿周期相对较短，一般为2.8个月左右。 大家在投稿前，一定要仔细阅读ASO的投稿指南，了解期刊的格式要求、引用风格、图表规范等方面的内容。 ASO支持开放获取（OA）模式出版，但需要版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 18:45:07 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：胸部肿瘤临床文章 4.17投稿 5.5意见返回来（小修） 5.17投回去 6.2接收，还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=)]

2024-08-22 04500 来自昆士兰

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：消化道肿瘤
经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行

52 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2236516, encodeId=69a922365167a, content=接收后ASO author reflection必须要写吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e15555908, createdName=ms4000000190354659, createdTime=Tue Nov 12 15:24:17 CST 2024, time=2024-11-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2241419, encodeId=7de122414192e, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审，是不是显示三个编辑就送审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ec8472153, createdName=ms2000000534427564, createdTime=Sun Dec 08 21:36:20 CST 2024, time=2024-12-08, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2237265, encodeId=4e71223e265a0, content=该期刊接受包括论著、摘要、信件和临床试验等多种形式的文章。 审稿周期相对较短，一般为2.8个月左右。 大家在投稿前，一定要仔细阅读ASO的投稿指南，了解期刊的格式要求、引用风格、图表规范等方面的内容。 ASO支持开放获取（OA）模式出版，但需要版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 18:45:07 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：胸部肿瘤临床文章 4.17投稿 5.5意见返回来（小修） 5.17投回去 6.2接收，还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=)]

2024-06-17 ms6000000157217108 来自吉林省

请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了

75 16

展开16条回复

[GetPortalCommentsPageByObjectIdResponse(id=2236516, encodeId=69a922365167a, content=接收后ASO author reflection必须要写吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e15555908, createdName=ms4000000190354659, createdTime=Tue Nov 12 15:24:17 CST 2024, time=2024-11-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2241419, encodeId=7de122414192e, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审，是不是显示三个编辑就送审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ec8472153, createdName=ms2000000534427564, createdTime=Sun Dec 08 21:36:20 CST 2024, time=2024-12-08, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2237265, encodeId=4e71223e265a0, content=该期刊接受包括论著、摘要、信件和临床试验等多种形式的文章。 审稿周期相对较短，一般为2.8个月左右。 大家在投稿前，一定要仔细阅读ASO的投稿指南，了解期刊的格式要求、引用风格、图表规范等方面的内容。 ASO支持开放获取（OA）模式出版，但需要版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 18:45:07 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：胸部肿瘤临床文章 4.17投稿 5.5意见返回来（小修） 5.17投回去 6.2接收，还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=)]

2024-12-08 ms2000000534427564 来自加利福尼亚

请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审，是不是显示三个编辑就送审了。

9 0

[GetPortalCommentsPageByObjectIdResponse(id=2236516, encodeId=69a922365167a, content=接收后ASO author reflection必须要写吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e15555908, createdName=ms4000000190354659, createdTime=Tue Nov 12 15:24:17 CST 2024, time=2024-11-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2241419, encodeId=7de122414192e, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审，是不是显示三个编辑就送审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ec8472153, createdName=ms2000000534427564, createdTime=Sun Dec 08 21:36:20 CST 2024, time=2024-12-08, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2237265, encodeId=4e71223e265a0, content=该期刊接受包括论著、摘要、信件和临床试验等多种形式的文章。 审稿周期相对较短，一般为2.8个月左右。 大家在投稿前，一定要仔细阅读ASO的投稿指南，了解期刊的格式要求、引用风格、图表规范等方面的内容。 ASO支持开放获取（OA）模式出版，但需要版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 18:45:07 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：胸部肿瘤临床文章 4.17投稿 5.5意见返回来（小修） 5.17投回去 6.2接收，还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=)]

2024-11-16 ms1000001788822136 来自上海

该期刊接受包括论著、摘要、信件和临床试验等多种形式的文章。
审稿周期相对较短，一般为2.8个月左右。
大家在投稿前，一定要仔细阅读ASO的投稿指南，了解期刊的格式要求、引用风格、图表规范等方面的内容。
ASO支持开放获取（OA）模式出版，但需要版面费。

18 0

[GetPortalCommentsPageByObjectIdResponse(id=2236516, encodeId=69a922365167a, content=接收后ASO author reflection必须要写吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e15555908, createdName=ms4000000190354659, createdTime=Tue Nov 12 15:24:17 CST 2024, time=2024-11-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2241419, encodeId=7de122414192e, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审，是不是显示三个编辑就送审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ec8472153, createdName=ms2000000534427564, createdTime=Sun Dec 08 21:36:20 CST 2024, time=2024-12-08, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2237265, encodeId=4e71223e265a0, content=该期刊接受包括论著、摘要、信件和临床试验等多种形式的文章。 审稿周期相对较短，一般为2.8个月左右。 大家在投稿前，一定要仔细阅读ASO的投稿指南，了解期刊的格式要求、引用风格、图表规范等方面的内容。 ASO支持开放获取（OA）模式出版，但需要版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 18:45:07 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：胸部肿瘤临床文章 4.17投稿 5.5意见返回来（小修） 5.17投回去 6.2接收，还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=)]

2024-01-23 新来的小李来自云南省

偏重的研究方向：肿瘤学;外科
经验分享：第二次投稿到接收50天左右，感觉很不错

132 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2236516, encodeId=69a922365167a, content=接收后ASO author reflection必须要写吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e15555908, createdName=ms4000000190354659, createdTime=Tue Nov 12 15:24:17 CST 2024, time=2024-11-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2241419, encodeId=7de122414192e, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审，是不是显示三个编辑就送审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ec8472153, createdName=ms2000000534427564, createdTime=Sun Dec 08 21:36:20 CST 2024, time=2024-12-08, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2237265, encodeId=4e71223e265a0, content=该期刊接受包括论著、摘要、信件和临床试验等多种形式的文章。 审稿周期相对较短，一般为2.8个月左右。 大家在投稿前，一定要仔细阅读ASO的投稿指南，了解期刊的格式要求、引用风格、图表规范等方面的内容。 ASO支持开放获取（OA）模式出版，但需要版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 18:45:07 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：胸部肿瘤临床文章 4.17投稿 5.5意见返回来（小修） 5.17投回去 6.2接收，还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=)]

2024-04-30 新来的小李来自贵州省

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：肿瘤外科
经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多

81 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2236516, encodeId=69a922365167a, content=接收后ASO author reflection必须要写吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e15555908, createdName=ms4000000190354659, createdTime=Tue Nov 12 15:24:17 CST 2024, time=2024-11-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2241419, encodeId=7de122414192e, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审，是不是显示三个编辑就送审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ec8472153, createdName=ms2000000534427564, createdTime=Sun Dec 08 21:36:20 CST 2024, time=2024-12-08, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2237265, encodeId=4e71223e265a0, content=该期刊接受包括论著、摘要、信件和临床试验等多种形式的文章。 审稿周期相对较短，一般为2.8个月左右。 大家在投稿前，一定要仔细阅读ASO的投稿指南，了解期刊的格式要求、引用风格、图表规范等方面的内容。 ASO支持开放获取（OA）模式出版，但需要版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 18:45:07 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：胸部肿瘤临床文章 4.17投稿 5.5意见返回来（小修） 5.17投回去 6.2接收，还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=)]

2021-06-04 12200887m48(暂无昵称)

审稿速度:1.0 | 投稿命中率:50.0
经验分享：胸部肿瘤临床文章 4.17投稿 5.5意见返回来（小修） 5.17投回去 6.2接收，还邀请写作者点评。

128 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=2236516, encodeId=69a922365167a, content=接收后ASO author reflection必须要写吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e15555908, createdName=ms4000000190354659, createdTime=Tue Nov 12 15:24:17 CST 2024, time=2024-11-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2241419, encodeId=7de122414192e, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审，是不是显示三个编辑就送审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ec8472153, createdName=ms2000000534427564, createdTime=Sun Dec 08 21:36:20 CST 2024, time=2024-12-08, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2237265, encodeId=4e71223e265a0, content=该期刊接受包括论著、摘要、信件和临床试验等多种形式的文章。 审稿周期相对较短，一般为2.8个月左右。 大家在投稿前，一定要仔细阅读ASO的投稿指南，了解期刊的格式要求、引用风格、图表规范等方面的内容。 ASO支持开放获取（OA）模式出版，但需要版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 18:45:07 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=970925, encodeId=97b29e0925bc, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：胸部肿瘤临床文章 4.17投稿 5.5意见返回来（小修） 5.17投回去 6.2接收，还邀请写作者点评。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68d02298711, createdName=12200887m48(暂无昵称), createdTime=Fri Jun 04 17:18:50 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=)]

2022-11-17 xiaoyudong222

9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗

138 7

展开7条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务